Alpine Global Management’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Alpine Global Management’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-55,287	Closed	-$279K	–	687
2022 Q1	$279K	Sell	55,287 -569,847	-91%	-$2.59M	0.06%	198
2021 Q4	$3.88M	Buy	625,134 +475,134	+317%	+$4.24M	0.57%	30
2021 Q3	$1.49M	Buy	+150,000	New	+$1.48M	0.34%	60

Other funds holding PEAR

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

SGA

SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return

Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return

TAA

TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Palantir Technologies Aventura, Florida $9.72M AUM 6.46% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alpine Global Management's PEAR Position: Q2 2022 in Review

Alpine Global Management sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2022, closing a stake of 55,287 shares — an estimated $279K sold.

Alpine Global Management first reported a position in PEAR in Q3 2021 and held it in 3 quarters. The position peaked at $3.88M in Q4 2021. 40 funds tracked by Wall St. Rank hold PEAR as of Q2 2022.

Alpine Global Management reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
Alpine Global Management sold 55,287 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2022, an estimated $279K.
Alpine Global Management first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q3 2021 and held it in 3 quarters.
Alpine Global Management's Pear Therapeutics, Inc. Class A Common Stock position peaked at $3.88M in Q4 2021.
40 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2022.

Based on Alpine Global Management's 13F filing for Q2 2022, filed 15 Aug 2022.